536748-05-7

Basic information

• Product Name: 3-fluoro-N,N-dimethyl-4-nitrobenzamide
• Synonyms: 3-fluoro-N,N-dimethyl-4-nitrobenzamide
• CAS NO: 536748-05-7
• Molecular Weight: 212.18
• Mol File: 536748-05-7.mol

Chemical Properties

• CAS DataBase Reference: 3-fluoro-N,N-dimethyl-4-nitrobenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-fluoro-N,N-dimethyl-4-nitrobenzamide(536748-05-7)
• EPA Substance Registry System: 3-fluoro-N,N-dimethyl-4-nitrobenzamide(536748-05-7)

Safety Data

• Hazardous Substances Data: 536748-05-7(Hazardous Substances Data)

Upstream product

• 403-21-4 3-fluoro-4-nitrobenzoic acid 
• 157665-51-5 3-fluoro-4-nitrobenzoyl chloride 
• 506-59-2 N,N-dimethylammonium chloride 

Downstream Products

• 1236281-72-3 tert-butyl 4-[4-(4-dimethylcarbamoyl-2-fluorophenylamino)-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl]piperidine-1-carboxylate 
• 536748-06-8 4-amino-3-fluoro-N,N-dimethylbenzamide 

Relevant articles and documents

Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy

Triple negative breast cancer (TNBC) is an aggressive disease with high relapse rates and few treatment options. Outlined in previous publications, we identified a series of potent, dual TTK/CLK2 inhibitors with strong efficacy in TNBC xenograft models. P

Preparation method of tergorazan

The invention belongs to the field of medicine preparation, and provides a novel preparation method of (S)-4-((5, 7-difluorochroman-4-yl) oxy)-N, N, 2-trimethyl-1H-benzo [d] imidazole-6-formamide (Tegoprazan). The preparation method provided by the invent

SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

NOVEL PYRROLOY2,3-d¨PYRIMIDINE COMPOUND

Disclosed is a novel pyrrolo[2,3-d]pyrimidine compound represented by formula [I] or a pharmacologically acceptable salt thereof, which has a GPR119 receptor agonistic activity and is useful for a pharmaceutical. In formula [I], E represents a group repre

Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade

The present invention provides compounds of Formula (I): wherein A, B, C, G, and W1 have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, processes for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.